MNDs are neurological disorders that destroy motor neurons, the cells that control skeletal muscle activity such as walking, breathing, speaking, and swallowing.

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...

Ahmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that it has received approval from USFDA to ...

Motor neuron disease usually refers to amyotrophic lateral sclerosis, but it can also refer to other kind of neurodegenerative disease that affect the motor neurons, such as progressive primary ...

When the lateral collateral ligament is completely torn, a surgical procedure is typically recommended to either repair or reconstruct the ligament. When the ligament is torn at the location of the ...

DNL343 For The Treatment Of Patients With Amyotrophic Lateral Sclerosis As I stated directly above, Denali Therapeutics reported that it had failed to meet the primary endpoint of the phase 2/3 ...

For the primary analysis, a total of 186 participants who received DNL343 treatment were compared to 139 participants who ...

Compared to placebo, the study did not meet the primary endpoint of efficacy in slowing disease progression. The primary endpoint was evaluated as a change in disease severity over time as ...

US-based biotechnology company Denali Therapeutics has reported that a Phase II/III trial of DNL343 for amyotrophic lateral sclerosis (ALS) failed to meet its primary endpoint. The primary analysis ...

Introduction: T regulatory cells (Tregs) inversely correlate with disease progression in Amyotrophic Lateral Sclerosis (ALS ... in the design of clinical trials for ALS therapy. The primary objective ...

Denali Therapeutics said the latest trial of its treatment for amyotrophic lateral sclerosis, or ALS, didn't meet its primary or secondary endpoints after 24 weeks.